Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00479323
Other study ID # 06-0093
Secondary ID
Status Completed
Phase Phase 1
First received May 24, 2007
Last updated December 22, 2016
Start date June 2007
Est. completion date August 2008

Study information

Verified date April 2011
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low. The purpose of this study is to give the pneumococcal vaccine to healthy volunteers and take serum blood samples in order to increase the reference serum supply. Study participants will include 250 healthy men and women, ages 18-45. Study procedures will include a physical exam, interviews, blood samples and blood testing. All volunteers will receive the pneumococcal vaccine in the deltoid muscle of the arm. Participants will be involved in the study for approximately 17 weeks.


Description:

Serum 89SF is a pooled sera from individuals vaccinated with a 23 valent pneumococcal polysaccharide vaccine collected in the late 1980s. The 89SF standard for ELISA is running low (2-3 year supply) and is insufficient to serve for opsinophagocytosis assay (OPA), which requires large volumes. The objective of this study is to immunize healthy volunteers with licensed polyvalent pneumococcal polysaccharide vaccine (Pneumovax 23) with subsequent blood donation in a quantity sufficient to make reference sera. Two hundred fifty volunteer subjects will be recruited from a total population of up to 600. Study participants will include healthy men and nonpregnant females, ages 18-45. Subjects will undergo physical examination by a licensed clinician, subject interview, and clinical laboratory and serologic testing. Potential subjects must provide written informed consent and meet all eligibility criteria. On Day 0, subjects will receive 0.5 mL pneumococcal vaccine (Pneumovax 23) in the deltoid muscle. Volunteers will remain in the clinic for 30 minutes following immunization for observation of any adverse reactions. Volunteers will return to clinic in 10-35 days following immunization to donate 1 unit (approximately 500 mL) of blood. Volunteers will return for a second donation of 1 unit of blood not less than 8 weeks and not more than 14 weeks following the first donation.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date August 2008
Est. primary completion date August 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Male or nonpregnant female between the ages of 18 to 45 and weighing a minimum of 110 pounds.

2. Women of childbearing potential (not surgically sterile or postmenopausal for >/= 1 year) must agree to practice adequate contraception (ie, barrier method, abstinence, intrauterine device, or licensed hormonal method) for the entire period while on protocol.

3. Women of childbearing potential must have a negative urine pregnancy test within 24 hours prior to vaccination and prior to each blood collection.

4. Participants must be afebrile and in general good health in the opinion of the investigator as determined by vital signs, medical history, and physical examination.

5. Subject laboratory tests, including hemoglobin, hematocrit, total white blood count and platelets, aspartate aminotransferase, alanine aminotransferase, and serum protein. All values must be within normal limits (WNL) except AST and ALT that must less than or equal to 1.5 X ULN and total serum protein >=6.0 gms; Males: hemoglobin >=13.5 gm/dL, hematocrit >=41% Females: hemoglobin >=12.5 gm/dL, hematocrit >=38%

6. Serology for hepatitis B (core antibody), C, HIV, rapid plasma reagin, immunoglobulin and HIV must be negative.

7. Subjects must have adequate venous access.

8. Participants must communicate an understanding of the protocol and provide written informed consent for the protocol.

Exclusion Criteria:

1. Has received any investigational drug or vaccine within the past 6 months or is currently in any phase of another clinical trial or intends to participate in another clinical trial in the next 6 months.

2. Has received any licensed inactivated vaccine within 2 weeks or licensed live vaccine within 4 weeks of screening.

3. Has a known allergy to any component of the Pneumovax 23 vaccine.

4. Has a history of receiving human blood or any derivative of human blood within the preceding 12 months.

5. Has no evidence of skin infection at the potential phlebotomy sites or evidence of systemic or generalized disease that could create a risk of contamination of the serum.

6. Has no history of viral hepatitis after the 11th birthday and no history of close contact with an individual diagnosed with viral hepatitis within the past year.

7. Is immunosuppressed as a result of underlying illness or treatment or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.

8. Long-term use of oral or parenteral steroids or high-dose inhaled steroids within the past 6 months.

9. Has a diagnosis of schizophrenia, bipolar disease, major psychiatric diagnosis, or has ever been hospitalized for a psychiatric illness.

10. Has a history of alcohol or drug abuse in the past 5 years.

11. Has any acute or chronic condition that, in the opinion of the investigator, would render vaccination or blood donation unsafe or the participant unable to meet the requirements of the protocol.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Pneumovax 23
Licensed pneumococcal vaccine (Pneumovax 23).

Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera. Duration of study. No
See also
  Status Clinical Trial Phase
Completed NCT02201030 - Immunogenicity and Safety Study of NBP606 in Healthy Infants Phase 3
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Completed NCT04031846 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Phase 3
Recruiting NCT05920499 - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage N/A
Completed NCT01215175 - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) Phase 1
Completed NCT02892812 - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Phase 1
Completed NCT02116998 - Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae Phase 2
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01193582 - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria Phase 4
Completed NCT00744263 - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults Phase 4
Completed NCT00492557 - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Phase 3
Completed NCT00195611 - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media Phase 4
Completed NCT00205803 - Study Evaluating Pneumococcal Vaccine in Healthy Infants Phase 1/Phase 2
Completed NCT00137605 - Early Versus Delayed Pneumococcal Vaccination in HIV Phase 1/Phase 2
Completed NCT02531373 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Phase 1/Phase 2
Completed NCT03615482 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) Phase 3
Completed NCT03565900 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Phase 3
Completed NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4
Completed NCT02547649 - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Phase 2
Completed NCT02573181 - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Phase 2